SQZ Biotechnologies Company (SQZ) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
200 ARSENAL YARDS BLVD., STE. 210 WATERTOWN, MA 02472 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2023 MRQ | 12/31/2022 | 12/31/2021 | 12/31/2020 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 63,709 | 143,513 | 170,357 | |||
| Cash and cash equivalents | 63,709 | 143,513 | 170,357 | |||
| Receivables | 384 | 3,000 | 1,892 | |||
| Prepaid expense | 4,111 | 4,027 | 4,032 | |||
| Other undisclosed current assets | 95 | 550 | ||||
| Total current assets: | 68,204 | 150,635 | 176,831 | |||
| Noncurrent Assets | ||||||
| Operating lease, right-of-use asset | 27,432 | 69,843 | 48,360 | |||
| Property, plant and equipment | 1,959 | 3,046 | 3,645 | |||
| Restricted cash and investments | 2,305 | 2,305 | 2,305 | |||
| Deferred costs | 323 | |||||
| Total noncurrent assets: | 31,696 | 75,517 | 54,310 | |||
| TOTAL ASSETS: | 99,900 | 226,152 | 231,141 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities | 11,404 | 10,781 | 11,066 | |||
| Accounts payable | 2,511 | 3,971 | 3,708 | |||
| Accrued liabilities | 8,893 | 6,810 | 7,358 | |||
| Deferred revenue | 715 | 12,507 | 25,917 | |||
| Restructuring reserve | 3,162 | |||||
| Other undisclosed current liabilities | 6,562 | 9,936 | 8,210 | |||
| Total current liabilities: | 21,843 | 33,224 | 45,193 | |||
| Noncurrent Liabilities | ||||||
| Long-term debt and lease obligation: | 59,756 | 38,885 | ||||
| Liabilities, other than long-term debt | 20,909 | 9,196 | 19,864 | |||
| Deferred revenue | 9,196 | 19,659 | ||||
| Other liabilities | 205 | |||||
| Operating lease, liability | 20,909 | 59,756 | 38,885 | |||
| Total noncurrent liabilities: | 20,909 | 68,952 | 58,749 | |||
| Total liabilities: | 42,752 | 102,176 | 103,942 | |||
| Equity | ||||||
| Equity, attributable to parent | 57,148 | 123,976 | 127,199 | |||
| Common stock | 29 | 28 | 25 | |||
| Additional paid in capital | 332,093 | 319,458 | 253,943 | |||
| Accumulated deficit | (274,974) | (195,510) | (126,769) | |||
| Total equity: | 57,148 | 123,976 | 127,199 | |||
| TOTAL LIABILITIES AND EQUITY: | 99,900 | 226,152 | 231,141 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|---|
| Revenues | 21,478 | 27,098 | 20,998 | ||
| Gross profit: | 21,478 | 27,098 | 20,998 | ||
| Operating expenses | (102,162) | (95,867) | (72,056) | ||
| Operating loss: | (80,684) | (68,769) | (51,058) | ||
| Nonoperating income | 1,220 | 28 | 537 | ||
| Investment income, nonoperating | 1,223 | 36 | 550 | ||
| Other nonoperating expense | (3) | (8) | (13) | ||
| Loss from continuing operations: | (79,464) | (68,741) | (50,521) | ||
| Loss before gain (loss) on sale of properties: | ✕ | (68,741) | (50,521) | ||
| Net loss available to common stockholders, diluted: | (79,464) | (68,741) | (50,521) | ||
Comprehensive Income ($ in thousands)
| 3/31/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|---|
| Net loss: | (79,464) | (68,741) | (50,521) | ||
| Other comprehensive loss | (30) | ||||
| Comprehensive loss, net of tax, attributable to parent: | (79,464) | (68,741) | (50,551) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.